Phaseline

Targets › BIRC2

BIRC2 (Baculoviral IAP repeat-containing protein 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling. (UniProt, Q13490)

Open in Phaseline: the race on BIRC2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Birinapant
cIAP1/cIAP2 inhibitor
BIRC3, BIRC2Phase 1Locally Recurrent Head and Neck Squamous Cell CarcinomaJul 2027

Conditions

Locally Recurrent Head and Neck Squamous Cell Carcinoma (1)

Modalities

small molecule (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

BIRC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.